Kaposi sarcoma–associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. This human gammaherpesvirus was discovered in 1994 by Drs. Yuan Chang and Patrick Moore. Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.
Kaposi sarcoma–associated herpesvirus: immunobiology, oncogenesis, and therapy

Dirk P. Dittmer and Blossom Damania

Kaposi sarcoma–associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. This human gammaherpesvirus was discovered in 1994 by Drs. Yuan Chang and Patrick Moore. Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus.

Introduction

Kaposi sarcoma (KS) is the most common cancer in individuals living with HIV/AIDS today (1, 2). While the introduction of effective HIV therapy was concurrent with a decline in the incidence of KS in the United States, KS incidence has stabilized and remained essentially level since 2000. In Africa, where KSHV and HIV infections are highly prevalent, KS is among the most common cancer type in men overall. In some sub-Saharan countries, KS is more prevalent than prostate cancer is in the US (3). As the expected lifespan of individuals living with HIV/AIDS increases, we foresee an increase in all cancers in this population, including KS.

Kaposi sarcoma–associated herpesvirus (KSHV) is necessary for KS development. KSHV DNA is found in all KS lesions (4, 5). KS prevalence follows KSHV seroprevalence, and in most cases fulminating KS is accompanied and preceded by a rise in KSHV viral load in blood. In addition to KS, KSHV is also the etiologic agent of the plasmablastic variant of multicentric Castleman’s disease (MCD) (6) and primary effusion lymphoma (PEL) (7, 8). Moreover, KSHV is the causative agent of KS-immune reconstitution syndrome (KS-IRIS) (9, 10) and KSHV-inflammatory cytokine syndrome (KICS) (11). However, not all KSHV infections lead to KSHV-associated conditions. The majority of primary KSHV infections have no clinical symptoms and, as with other human oncogenic viruses, cancer emerges only after decades of dormancy. KSHV can be transmitted via asymptomatic oral shedding as well as through bodily fluids (12–14). KSHV can infect many different types of cells, including endothelial cells, B lymphocytes, monocytes, dendritic cells (DCs), and epithelial cells. The virus consistently immortalizes, but rarely transforms, primary cells in culture (15–19). It is only under special circumstances and perhaps upon infection of rare progenitor cells with stem cell properties that the interplay between virus and host leads to a fully transformed state.

Why is the human immune system so powerful in suppressing disease, yet can never eliminate this pathogen? Like all herpesviruses, KSHV establishes lifelong infection in the host and molecular latency in cells in culture. KS is primarily the consequence of systemic viral reactivation from a latent reservoir, most likely a lymph node–resident B cell (20–23). Prior to the emergence of HIV, endemic KS in sub-Saharan Africa was a disease of both children and adults, and classic KS was a disease of elderly men in the Mediterranean region. Today, KS also develops with higher frequency in HIV-infected individuals (HIV-associated KS) compared with HIV-negative individuals, as well as in solid organ transplant recipients (transplant KS). Thus, it appears that KS develops in response to severe T cell depletion or inactivation. Infant, aging-, chemical-, or HIV-induced immune deficiency is an essential cofactor for the development of KS.

Primary infection and the innate immune response to KSHV

KSHV is thought to enter cells predominantly through the endocytic pathway. Viral attachment involves several different receptor binding proteins on the virion. KSHV can infect multiple cell types, including B cells, endothelial cells, monocytes, and DCs, and hence uses multiple viral receptors to enter the host cell. One such receptor is the gB glycoprotein, which contains an integrin-binding RGD (Arg-Gly-Asp) motif that plays a role in virion binding and entry of endothelial cells (24–26). Activated B cells, macrophages, and DCs express a DC-specific ICAM-3-grabbing non-integrin (DC-SIGN; CD209) that facilitates KSHV infection in these cell types (27, 28). The cysteine transporter (xCT) can also serve as a receptor for the virus (29).

KSHV is thought to enter cells predominantly through the endocytic pathway (30–32). During its entry into the host cell, the virus encounters multiple innate immune sensors that activate an antiviral response. It is likely that the activation of such innate immune responses during primary infection induces the virus to enter molecular latency, which is a more quiescent and less immunogenic phase of the lifecycle.
production and suppresses viral gene expression following de novo infection with KSHV as well as during viral reactivation (39, 40).

**NLRs.** NLR family members can form inflammasomes, a complex comprised of an NLR protein, ASC, and pro-caspase-1. NLRs sense PAMPs, and activation of the NLR inflammasomes results in cleavage and production of active IL-1β and IL-18, which are proinflammatory cytokines. Primary infection with KSHV activates NLRP1 and NLRP3 (41, 42) and potentially other NLRs.

**ALRs.** Like NLRs, ALR family members can also form inflammasomes to activate proinflammatory cytokine signaling. Primary infection with KSHV has been shown to activate the ALR family member interferon gamma–inducible protein 16 (IFI16) (43, 44). It was additionally reported that IFI16 can detect KSHV in latently infected cells (43).

**cGAS-STING.** Cyclic GMP-AMP (cGAMP) synthase (cGAS) and STING are members of the cytosolic DNA-sensing pathway. This cGAS-STING pathway appears to sense KSHV during both primary infection and reactivation from latency in multiple cell types (45–47).

There seems to exist a delicate equilibrium between the virus and host response to infection. Although innate immune activation might help KSHV enter a latent, quiescent phase inside the infected cell and induce expansion of latently infected cells, a high degree of innate immune response facilitates killing of the infected cell and ultimately prevents the establishment of latency. To counter the host response to viral infection and reactivation, KSHV encodes many viral genes that blunt innate immune signaling pathways. Some of these viral products are summarized in Figure 1 and are described below.

**Viral interferon regulatory factors.** KSHV encodes four viral interferon regulatory factors (vIRFs), three of which ablate cellular IRF signaling and inhibit the production of type I IFNs, including IFN-α and IFN-β (reviewed in ref. 48). KSHV vIRFs have been shown to inhibit IFN production that lies downstream of TLR3 activation (49), MAVS activation (50), and cGAS-STING activation (45). KSHV vIRF1 also inhibits the function of IFN-induced genes such as ISG15 (51) and the transcription of TLR4 (37).

**Complement regulatory proteins.** KSHV encodes the complement regulatory protein KCP, which is encoded by ORF4. KCP is part of the virion and functions as a cofactor for factor I-mediated cleavage of C3b and C4b, the complement system’s opsonizing factors (52, 53). KSHV has also been reported to exploit the host complement system to promote viral persistent infection (54).

**Tegument proteins.** Tegument proteins are a characteristic feature of all herpesviruses, and a large number of them are deposited into the cytoplasm following virion fusion and capsid release.

Cells infected with viruses such as KSHV trigger an innate immune response through pattern recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs) and lead to the production of interferon and proinflammatory cytokines. It is important to note that each cell type expresses its own unique set of PRRs. There are many different PRRs including TLRs, retinoic acid–like receptors (RLRs), NLRs, absent in melanoma 2 (AIM2)-like receptors (ALRs), and cytosolic DNA sensors (reviewed in ref. 33). Members of the NLR, ALR, and RLR families can form inflammasomes that, upon activation, lead to the production of IL-1β and IL-18 (34). KSHV infection and/or reactivation activates a multitude of PRRs in different cell types; these are described below.

**TLRs.** Following primary infection, KSHV has been shown to activate the RNA sensor TLR3 in monocytes, (35) and the DNA sensor TLR9 in plasmacytoid DCs (pDCs) (36). Activation of either TLR results in interferon production and upregulation of cytokines and chemokines. KSHV also activates TLR4 signaling that likely occurs through recognition of the viral glycoproteins gB and K8.1 (37). Stimulation of TLR7/8 in PEL cells has been shown to lead to reactivation from latency (38).

**RLRs.** The cytosolic RNA sensor RIG-I and its adaptor protein, mitochondrial antiviral signaling protein (MAVS), induces IFN-β production and suppresses viral gene expression following de novo infection with KSHV as well as during viral reactivation (39, 40).

**NLRs.** NLR family members can form inflammasomes, a complex comprised of an NLR protein, ASC, and pro-caspase-1. NLRs sense PAMPs, and activation of the NLR inflammasomes results in cleavage and production of active IL-1β and IL-18, which are proinflammatory cytokines. Primary infection with KSHV activates NLRP1 and NLRP3 (41, 42) and potentially other NLRs.

**ALRs.** Like NLRs, ALR family members can also form inflammasomes to activate proinflammatory cytokine signaling. Primary infection with KSHV has been shown to activate the ALR family member interferon gamma–inducible protein 16 (IFI16) (43, 44). It was additionally reported that IFI16 can detect KSHV in latently infected cells (43).

**cGAS-STING.** Cyclic GMP-AMP (cGAMP) synthase (cGAS) and STING are members of the cytosolic DNA-sensing pathway. This cGAS-STING pathway appears to sense KSHV during both primary infection and reactivation from latency in multiple cell types (45–47).

There seems to exist a delicate equilibrium between the virus and host response to infection. Although innate immune activation might help KSHV enter a latent, quiescent phase inside the infected cell and induce expansion of latently infected cells, a high degree of innate immune response facilitates killing of the infected cell and ultimately prevents the establishment of latency. To counter the host response to viral infection and reactivation, KSHV encodes many viral genes that blunt innate immune signaling pathways. Some of these viral products are summarized in Figure 1 and are described below.

**Viral interferon regulatory factors.** KSHV encodes four viral interferon regulatory factors (vIRFs), three of which ablate cellular IRF signaling and inhibit the production of type I IFNs, including IFN-α and IFN-β (reviewed in ref. 48). KSHV vIRFs have been shown to inhibit IFN production that lies downstream of TLR3 activation (49), MAVS activation (50), and cGAS-STING activation (45). KSHV vIRF1 also inhibits the function of IFN-induced genes such as ISG15 (51) and the transcription of TLR4 (37).

**Complement regulatory proteins.** KSHV encodes the complement regulatory protein KCP, which is encoded by ORF4. KCP is part of the virion and functions as a cofactor for factor I-mediated cleavage of C3b and C4b, the complement system’s opsonizing factors (52, 53). KSHV has also been reported to exploit the host complement system to promote viral persistent infection (54).

**Tegument proteins.** Tegument proteins are a characteristic feature of all herpesviruses, and a large number of them are deposited into the cytoplasm following virion fusion and capsid release.

Figure 1. Innate immune evasion by KSHV. KSHV encodes multiple viral proteins that inhibit innate immune pathways. (i) KSHV-mediated activation of TLRs and RIG-I triggers interferon and IFN-β production following primary infection. (ii) KSHV Rta, ORF45, and vIRF1, -2, and -3 block cellular IRFs from activating interferon-responsive genes. (iii) KSHV LANA, ORF52, and vIRF1 block the cGAS-STING DNA-sensing pathway. (iv) KSHV ORF63 inhibits NLRP1 and NLRP3 inflammasome activation and KCP/ORF4 promotes KSHV pathogenesis by helping the virus to evade complement.
KSHV ORF45 is a tegument protein that blocks IRF7 phosphorylation and activation of type I IFN responses (55, 56). ORF64 is another conserved herpesviral tegument protein that encodes potent deubiquitinating activity (57). ORF64 can reduce TRIM25-dependent ubiquitination and activation of RIG-I, thereby inhibiting this sensing pathway in KSHV-infected cells (40).

**DNA-binding proteins.** Although it is primarily a DNA-binding protein and transcription factor, KSHV Rta/ORF50 can also induce the degradation of innate immune sensors such as IRF7, TLR3, and myeloid differentiation factor 88 (MyD88) (58–61). The latency-associated nuclear antigen (LANA) is another DNA-binding protein that inhibits IFN-β induction (62) and the transcription of IFN-γ-inducible genes (63). Recently, it was shown that cytoplasmic variants of LANA can inhibit the cGAS-STING DNA-sensing pathway by directly binding to cGAS (47). Interestingly, another KSHV open reading frame, ORF52, was similarly shown to bind and inhibit cGAS enzymatic activity. Infection with an ORF52-deficient virus in endothelial cells resulted in increased cGAS signaling (46).

Furthermore, NLRP1 and NLRP3 inflammasome activation is inhibited by the tegument protein KSHV ORF63 during de novo infection, resulting in reduced IL-1β and IL-18 production. ORF63 binds to NLRP1 and interferes with the interaction between NLRP1 and pro-caspase-1 (42).

In addition to the innate immune responses described above, adaptive immune responses also play an important role in KSHV pathogenesis. KSHV expresses proteins that affect antigen presentation, B cell targeting, MHC class I display, and neutrophil and basophil activation. The KSHV-infected cell presents antigenic peptides from the virus in complex with MHC class I to cytotoxic T lymphocytes (CTLs) (64–66). Additionally, KSHV-infected B cells stimulate activation-induced cytidine deaminase (AID) expression and are targeted for elimination by NK cells through upregulation of NKG2D ligands (67). KSHV also encodes genes that inhibit these immune responses. KSHV K3/MIR1 and K5/MIR2 are ubiquitin ligases that inhibit MHC class I display (68, 69). K3/MIR1 downregulates four HLA allotypes (HLA-A, B, C, and E), while K5/MIR2 downregulates HLA-A and HLA-B (70, 71). K3 and K5 can also downregulate CD1d (72) and IFN-γ receptor 1 (IFNGR1) (73). K5 hinders expression of ICAM-1 and the costimulatory molecule B7-2 (CD86) (74, 75). It also downregulates the NKG2D ligands, MHC class I-related chain A (MICA), MICB, and the Nkp80 ligand, activation-induced C-type lectin (AICL) (76). KSHV vCD200, also known as viral OX2, is a homolog of cellular CD200 that is broadly expressed and suppresses neutrophil and basophil activation (77) as well as activation of macrophages (78). vCD200 can also function as a negative regulator of antigen-specific T cell responses, including inhibition of IFN-γ production and CD107a mobilization (79).

KSHV viral IL-6 (vIL-6) has also been reported to block interferon signaling. IFN-α directly activates viral IL-6 gene expression through IFN-inducible sites in the vIL-6 promoter. vIL-6 then subsequently blocks IFN signaling by inhibiting IFN induction of p21 and also downregulating the IFN receptor-mediated phosphorylation of TYK2 kinase, thereby dampening JAK-STAT signaling (80).

Finally, KSHV encodes several viral macrophage inflammatory proteins (vMIPs). KSHV vMIP-II inhibits chemotaxis and recruitment of monocytes (81) as well as NK cells (82). KSHV vMIP-II is an agonist for CCR8, a chemokine receptor that is preferentially expressed on polarized Th2 T cells (83). Similarly, KSHV vMIP-III serves as an agonist for the cellular chemokine receptor CCR4, which is also expressed by Th2 T cells (84). Hence, the KSHV vMIPs skew T cell responses towards a Th2-type lymphocytic response, and this may play a role in subverting the host immune response.

**Latent KSHV infection and reactivation**

KSHV successfully subverts the cellular innate immune response to establish a lifelong latent reservoir in the infected host, primarily in B cells. The virus has evolved a number of mechanisms to ensure that virally infected B cells outcompete their uninfected counterparts, which in the extreme leads to B cell hyperplasia, such as MCD (6, 21), or B cell neoplasia, such as PEL (7). These include inhibiting apoptosis, overcoming G1 phase arrest, lowering the threshold for B cell receptor (BCR) activation, and providing ligand-independent progrowth signals. In addition to B cells, this virus can also enter CD34 cells, T cells, monocytes, and pDCs (36, 85–88), though it is unclear if these cell types contribute to systemic persistence or serve as sentinels to detect infection. Epstein-Barr virus (EBV) also uses B cells as the predominant latent reservoir, as does murine herpesvirus 68 (reviewed in ref. 89); however, there are important biological differences between latent infection in B cells in KSHV and other herpesviruses. EBV is easily detected in blood in circulating CD38+ memory B cells, which typically emerge from the germinal center. In contrast, KSHV is not readily detectable in circulating B cells (23), and KSHV viral loads in blood are 10- to 100-fold lower than those of EBV or human CMV. These observations suggest that tissue-resident B cells are the predominant latent reservoir for KSHV.

The deepest insights about the biology of KSHV prior to disease come from studying the related murine gammaherpesvirus 68 (MHV-68) and from genetically engineered mouse models. In mouse models, it was possible to define B cell tropism through functional phenotypes (21). Studies in MHV-68 defined the distinction between establishment of latency, which drives the size of the latent reservoir, and persistence of the latent reservoir, i.e., long-term survival of infected cells that are still capable of reactivation (for recent examples see refs. 90–92). We do not know the dynamics of latently infected cells in humans and have only just begun to decipher the physiological signals that modulate reactivation events and thereby transmission and disease in patients.

Histone deacetylation reactivates KSHV. Vorinostat (also known as SAHA) and valproic acid induce reactivation in culture and in patients (93–95). Sodium butyrate and phorbol esters reactivate KSHV from PEL, though only a fraction of episomes is competent for reactivation at any given time (96, 97). The majority of the KSHV episome is methylated, transcriptionally silent, and decorated with histone markers, indicative of inactive chromatin (96, 98–101). These markers of methylation are established early in infection and maintained by cellular chromatin remodelers, and organized by CCCTC-binding factor (a zinc finger protein, also known as CTCF) recognition elements (100). During latency, the virus actively engages host chromatin modulators (Figure 2). For instance, LANA binds to histones H2A and H2B as well as MECP2, and to the BET family proteins BRD2 and BRD3 (102–104).
The KSHV Rta protein (also known as ORF50) is necessary and sufficient to initiate KSHV reactivation (105, 106). Rta is a potent transcriptional activator that can bind DNA directly or through RBP-Jκ (107). Rta reverses and overrides chromatin-silencing modifications, and deletion of Rta renders MHV-68 unable to reactivate from latency. In subsequent steps, other viral proteins such as K-bZIP augment the action of Rta to ensure robust and complete viral replication and virion formation. If Rta is the master regulator of reactivation from latency, what regulates Rta expression and Rta function? Here the experimental evidence is murkier. KSHV LANA and viral miRNAs counteract Rta and rapidly drive the virus into latency upon infection of primary endothelial cells, whereas in other environments Rta prevails (108–110). It is also worth mentioning that viral reactivation can occur in an Rta-independent fashion (111).

More research is needed to identify physiological triggers of KSHV reactivation as potential targets of disease prevention. These are likely to depend on conserved as well as cell- and microenvironment-specific signaling pathways (112). KSHV reactivation can be induced by IFN-γ, but not IFN-α. KSHV reactivation is induced by TLR7/8 signaling, and reactivation is enhanced by deletion of RIG-I and MAVS (38, 39). In artificially infected Burkitt lymphoma B cells (BJAB cells), B cell receptor crosslinking can reactivate KSHV (113), though PELs are BCR negative. Different sets of events may trigger KSHV reactivation in the oral cavity versus endothelial cells.

**Update on LANA function and structure**

LANA binds the viral terminal repeats, specifically two sequence-conserved, high-affinity binding sites (LBS1 and LBS2) and a more divergent third, low-affinity site (114–116). LANA can be thought of as a dumbbell-like structure in which a stalk of internal repeats separates the two globular terminal regions. The stalk length is variable and nonessential for LANA’s nuclear functions, as a direct N-to-C terminal domain fusion retains the latency-supporting functions. Whereas the C-terminal end of LANA binds KSHV DNA directly, the N-terminus (and perhaps regions in the C-terminus as well) contact cellular chromosome-associated proteins, such as histones H2A and H2B and others (104). The crystal structures of the KSHV LANA and MHV-68 LANA DNA-binding domains were solved (102, 103, 116, 117). This work identifies the DNA contact residues and reveals a folding pattern analogous to EBV EBNA1 and HPV E2.

LANA-episome complexes adopt higher-order structures in the nucleus of infected cells and appear as a characteristic punctate pattern by immunofluorescence (114, 118, 119). Initially considered a somewhat underwhelming feature, these “LANA dots” have emerged as the diagnostic gold standard to identify KSHV-infected cells and to make the diagnosis of KS and PEL (114, 118, 119). The number of LANA dots correlates with the number of KSHV plasmids in an infected cell. During mitosis, LANA, and by inference KSHV plasmids, decorates condensed chromosomes, thereby facilitating proper and equal partitioning of the latent viral genomes into daughter cells. Loss-of-function LANA mutants in the context of the viral genome remain competent for lytic replication, but fail to establish and maintain latency in KSHV and the related MHV-68. Ablation of LANA in PEL is incompatible with growth. Thus, LANA can be considered essential for KSHV-associated lymphomagenesis. However, interpreting genetic experiments for LANA is rather complex, since tethering the KSHV plasmids to the host genome is not the only function of LANA. LANA also binds a large number of cellular proteins to modulate their functions, including p53 and many other proteins with specialized functions (120, 121). Most recently, cytoplasmic variants of LANA have been described (122), and whole-genome screens have highlighted the importance of LANA during KSHV primary infection (45, 47).
Viral miRNAs support viral infection and latent persistence

A recently emerged common feature among all herpesviruses is the utilization of virally encoded miRNAs as a means to modulate the host cell during latency and primary infection. In Marek’s disease virus, a B cell–tropic alpha herpesvirus of chickens, viral miRNAs are the primary driver of oncopogenesis. Recently, KSHV mir-K12-10a was identified as the molecular driver behind the in vitro transforming phenotype of KSHV Kaposin, since it is embedded within the open reading frame of this protein (123). The role of the KSHV miRNAs is often more subtle, but it is important to bear in mind that virally encoded miRNAs account for 50% or more of all miRNAs in a KSHV-infected B cell. KSHV encodes 12 pre-miRNA loci, which can give rise to 24 mature miRNAs and many more if alternative processing is considered (124–126). Many of the viral miRNAs are also secreted into pleural fluid and circulate in the blood of KS patients (127). Thus, they serve as biomarkers of latent infection.

In general, viral miRNAs target specific cellular mRNAs, leading to their degradation (via an siRNA-like mechanism) and inhibition of mRNA-directed translation. miRNAs are developmentally regulated and fine-tune lineage differentiation and cellular signaling. The targets of the KSHV miRNAs have been established through a series of comprehensive biochemical studies (128–131). Thus far, miRNA studies have been constrained by sensitivity limits for detection of individual miRNAs and for the discovery of miRNA-target interactions. Targets with functions that seem to befit the biology of B cell development, endothelial cell differentiation, and KSHV (such as BACH1, xCT, MAF, and others) have been individually validated (132–134). These are by no means the only targets, and it is anticipated that additional targets will be identified in the future.

Cellular miRNA-155 is central to B cell lineage development in the germinal center. Downregulation of miRNA-155 is associated with terminal differentiation of plasma cells and loss of proliferative potential. Conversely, ectopic expression of miRNA-155 is associated with hyperproliferation and lymphoma. EBV relies on endogenous miRNA-155 to drive lymphoblastoid cell line immortalization (129, 135). Similarly, KSHV encodes an ortholog of miRNA-155 named miRNA-K12-11 that contains 100% seed sequence identity (136, 137). This KSHV ortholog complements the proliferative deficits observed in mir-155-deficient mice and drives lymphoma in a CD34 reconstitution model (138, 139). While miR-155 is the first and best-studied viral ortholog of a cellular miRNA, it is not the only one. As our appreciation for the complexities of host cell miRNA function and regulation grows, we can expect to gain new insights into the biology of KSHV miRNAs as well.

Genomic explorations of KS and PEL

Only a small fraction of KSHV-infected children develop KS, just as only a small fraction of EBV-infected children develop Burkitt lymphoma. In the context of solid organ transplantation, only a fraction of KSHV-seropositive transplant recipients develop KS, similar to the small fraction of EBV-seropositive transplant recipients that develop posttransplant lymphoproliferative disease, a condition associated with EBV infection of B cells after therapeutic immunosuppression. Currently, there is no screening of organ donors for KSHV positivity, although screening for KSHV in donors is warranted. KS that develops in transplant patients is usually a late complication, developing several months after the onset of immune suppression therapy. By contrast, the onset of herpes simplex and CMV reactivation disease is more immediate, often necessitating acyclovir prophylaxis for the first 6 months after transplantation. The delayed emergence of KS vis-à-vis clinical diseases associated with these other herpesviruses suggests that in addition to KSHV and in addition to immune deficiency, genomic alterations may contribute to KSHV-associated neoplasia.

Family linkage studies in classic KS support the notion of susceptibility loci for KS (140–142). Whereas t(8;14) and related translocations targeting MYC are the defining genomic event in EBV-related Burkitt’s lymphoma, MYC translocations are not present in PEL. Rather, the KSHV viral protein LANA drives MYC overexpression (143, 144). Comparative genome hybridization uncovered fragile histidine triad (FHIT) deletion as overrepresented in PELs, and targeted sequencing studies identified a polymorphism in IL-1 receptor–associated kinase 1 (IRAK1) as significantly overrepresented in PELs (145, 146). Moreover, IRAK1 signaling is required for PEL growth. This observation parallels Waldenstrom macroglobulinenia and a fraction of diffuse large B cell lymphomas, where gain-of-function mutations in MyD88, the upstream partner of IRAK1, are present (147, 148).

It is important, however, to recognize that the rarity of PEL and classic KS incidence hinders genomic explorations, which limits the statistical significance of any association.

PTEN, p53, and Rb are not deleted in PEL or KS; rather, they are inactivated posttranslationally, e.g., by direct binding to LANA, or via expression of the CDK1-resistant viral cyclin homolog vCYC (149). This may explain why KS is initially responsive to DNA-damaging chemotherapy. Susceptibility to etoposide correlates with p53 mutation status in PEL, and p53 activation by nutlin-3 leads to apoptosis (120, 121). In KS and PEL, the human genome is dynamic and the host mutational landscape is shaped by selection during clonal evolution of the tumor just as it is for...
non–infection-associated cancers. The presence of KSHV modifies a particular pattern of mutations, but these mutations affect the same progrowth and antiapoptosis pathways as in other cancers. However, the interpretation of signature mutations becomes complicated in light of their role in infection-associated cancers, such as PEL or KS. Whether a particular event has been selected as a driver of tumorigenesis after viral infection or if it represents a susceptibility allele for the primary infection event (or asymptomatic, systemic persistence) is not always apparent.

Only recently have whole KSHV genome sequences become available from patients and primary biopsies (150, 151). These sequences augment extensive studies that trace the origin and evolution of KSHV based on single-gene analyses (152). KSHV sequences show overall structural concordance and limited variation, as would be expected since viral replication is the result of error-correcting, DNA-dependent DNA polymerases (the cellular DNA polymerase during latency and a viral KSHV-encoded DNA polymerase during lytic replication). During B cell latency, multiple copies of the KSHV plasmid are maintained, replicated by the host DNA polymerase, and propagated to daughter cells during host cell division events. As yet, there is no evidence for integration of the KSHV genome. Nevertheless, defective variants have been described and are expected to arise in the context of clonal expansion of PEL or advanced KS. KSHV noncoding regions such as the miRNA locus show more variation, and differences in miRNA sequences correlate with processing and function (153–155). The number of terminal repeats in the KSHV genome is highly variable and can be used for strain typing (156, 157). Likewise, membrane proteins that are subject to immune recognition, such as K1 and K15, contain hypervariable regions in the extracellular domains (158–160).

Targeted treatment approaches to KSHV-associated cancers

KS is a disease of endothelial cells, and details of its pathobiology have been extensively reviewed. KS is among the most angiogenic cancers known to arise in humans. If we can decipher which factors drive KS and which treatments interrupt KS angiogenesis, then we will have potent leads for other cancers that depend on angiogenesis. VEGF, stem cell factor (SCF, also known as KIT ligand), and platelet-derived growth factor (PDGF) are the best-characterized paracrine drivers of KS angiogenesis (161, 162), and these are the target of a number of therapeutic approaches for KS. VEGF-neutralizing antibodies (bevacizumab) and receptor tyrosine kinase (RTK) inhibitors, such as imatinib, have efficacy in KS (163, 164), although their therapeutic impact as single agents is limited.

PI3K activates the cell survival kinase AKT, which subsequently activates mTOR. Rapamycin (also known as sirolimus) has clinical activity against KS (173, 174). Switching from cyclosporine A to rapamycin as the primary immunosuppressant has become the first line of therapy for transplant KS. The clinical phenotype can be recapitated in preclinical models of KS and PEL (175–179). In KS, targeting mTOR was associated with a decrease in VEGF production. In PEL, rapamycin reduced IL-6 and IL-10 secretion, and inactivating PI3K and mTOR together had more potent antitumor activity than inhibiting mTOR alone (180). The latter findings provide a guide path for the development of next-generation PI3K/AKT/mTOR targeting strategies against KS.

Therapies that target immunomodulatory mechanisms also hold promise for KS, and KSHV-associated diseases. Siltuximab, a humanized anti–IL-6 antibody, has been FDA approved for classic Castleman’s disease (181), and is likely to also show efficacy against MCD. A pilot clinical trial of tocilizumab, a humanized antibody against the IL-6 receptor, is open for MCD (NCT01441063). Blocking IL-6 stymies PEL growth in preclinical models (182). Hsp90 inhibitors exhibited nanomolar EC50 against PEL and KS in three independent studies (183–185). PEIs are also extremely sensitive to NF-κB pathway inhibitors such as bortezomib (186, 187), and a clinical trial with adjuvant bortezomib is ongoing. Other targets with encouraging preclinical results are NOTCH (188–192), and the KSHV receptor, ephrin receptor A2 (EphA2) (193–195).

While some individual AIDS-KS lesions respond to combination antiretroviral therapy (cART) and the ensuing immune reconstitution, others do not. In the US, one third of KS cases now develop in HIV patients with no detectable HIV viral load and near-normal CD4 counts (196, 197). This type of KS no longer signifies terminal AIDS. In sub-Saharan Africa, where KS remains the most common disease among HIV patients and the most common AIDS-presenting symptom, initiating CART can lead to KS exacerbation in KS-IRIS (9, 10). At least two large clinical trials are currently underway to determine if it is better to give cART and chemotherapy sequentially or together, and which chemotherapy is best suited for which stage of KS (198, 199). Liposomal doxorubicin, daunorubicin, other anthracycline formulations, and taxol constitute the mainstay of KS treatment.

The need for a better understanding of KSHV remains

KS is the most common cancer in males in many African countries and remains the most common cancer in HIV-positive persons in countries where cART coverage is near universal. As with all diseases, a detailed molecular understanding of the primary etiologic agent, i.e., KSHV, forms the basis for the development of targeted therapeutics. If it is possible to cure latent HIV virus, it should also be possible to cure latent KSHV. LANA represents the most direct target for such an approach, although as described above, KSHV latency and KSHV persistence involve many viral proteins as well as viral miRNAs. Any of these proteins could become a clinically tractable target. A viral cure is limited without preventing subsequent reinfection. Pre-exposure prophylaxis may be possible for transplant patients or other at-risk populations, though the side effects of current antivirals (e.g., ganciclovir) are rather severe. A preventative vaccine would provide the best approach.
Is it time for a KSHV vaccine?

We would argue that KSHV vaccine development is needed, and that both preventative and therapeutic KSHV vaccines would be of benefit. KSHV transmission among infants is similar to that of all other herpesviruses; by puberty, greater than 80% of children seroconvert in KSHV endemic regions. By contrast, transmission among adults in many parts of the world (excluding Africa and the Mediterranean) is so poor that repeated contact or immunodeficiency, as in high-risk populations, is needed to sustain the virus at a greater than 5% population-wide prevalence. This suggests that only a fraction of exposures leads to establishment of latency and eventual disease. Systemically circulating and salivary levels of KSHV in asymptomatic persons are orders of magnitude lower than those of EBV, herpes simplex virus, or human CMV (13, 14, 200). Evidence of KSHV superinfection in immune-competent persons is limited. A little priming of the immune system by a vaccine prior to establishment of latency may be all that is needed to eradicate KSHV and KS-associated diseases from the human population.

Acknowledgments

We apologize for not citing many publications due to limits on reference numbers per journal policy. We thank members of the Dittmer and Damania labs and all our colleagues for stimulating discussions. Our work is supported by Public Health Service grants CA019014, CA163217, DE018304, DE023946, DE018281, and CA096500 from the National Cancer Institute (NCI) and the Institute of Dental and Craniofacial Research (NIDCR). DPD is an investigator of the AIDS malignancies clinical trial consortium (AMC). BD is a Leukemia and Lymphoma Society Scholar, and a Burroughs Wellcome Fund Investigator in Infectious Disease.

Address correspondence to: Blossom Damania, 450 West Drive, CB# 7295, Rm 32-026, Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. Phone: 919.843.6011; E-mail: damania@med.unc.edu.
3172
jci.org Volume 126 Number 9 September 2016

The Journal of Clinical Investigation


REVIEW


171. Chen W, Sin SH, Wen KW, Damania B, Dittmer D.
DP. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. *PLoS Pathog*. 2012;8(1):e1003048.


